A potential multiple resonance mechanism by which weak magnetic fields affect molecules and medical problems: the example of melatonin and experimental "multiple sclerosis"
Authors not listed · 2006
Extremely weak magnetic fields may therapeutically affect melatonin through resonance mechanisms at specific frequencies and concentrations.
Plain English Summary
This theoretical study by Dr. Michael Persinger proposes that extremely weak magnetic fields in the nanoTesla range (35-70 nT at 7 Hz frequency) could affect melatonin molecules and potentially treat conditions like multiple sclerosis. The hypothesis suggests these fields work through a resonance mechanism that depends on melatonin concentration levels in specific body tissues.
Why This Matters
This research represents a fascinating intersection of biophysics and therapeutic EMF applications, though it remains theoretical rather than experimental. Persinger's hypothesis that nanoTesla-range magnetic fields could therapeutically modulate melatonin function challenges conventional thinking about EMF dose-response relationships. The proposed 7 Hz frequency aligns with natural brain rhythms, suggesting potential biological relevance. What makes this particularly intriguing is the extremely low field strengths involved - thousands of times weaker than typical EMF exposure concerns, yet potentially bioactive through resonance mechanisms. While the multiple sclerosis application remains speculative, this work highlights how our understanding of EMF bioeffects may need to account for complex resonance phenomena rather than simple thermal heating models.
Exposure Information
Specific exposure levels were not quantified in this study.
Show BibTeX
@article{a_potential_multiple_resonance_mechanism_by_which_weak_magnetic_fields_affect_molecules_and_medical_problems_the_example_of_melatonin_and_experimental_multiple_sclerosis_ce1681,
author = {Unknown},
title = {A potential multiple resonance mechanism by which weak magnetic fields affect molecules and medical problems: the example of melatonin and experimental "multiple sclerosis"},
year = {2006},
doi = {10.1016/J.MEHY.2005.09.044},
}